|Title:||Development of user-friendly cancer risk assessment tools for clinical settings (CANRISK)|
|Project Description:||The main objective of the CanRisk programme is to develop and validate quantitative tools for cancer risk-stratification and prevention that take advantage of discoveries in both cancer genomics and epidemiology. The primary focus is the analytical work and the development of the necessary methodologies and technologies for developing the proposed cancer risk prediction models and proof-of-concept tools.
The current proposal will add value to primary research by addressing the following specific research questions:
1. What improvement can be achieved in individualised risk prediction for breast, ovarian and prostate cancer, by combining data on all genetic, lifestyle/hormonal, clinical and imaging risk factors?
The third question is the component we are working on and focuses on the third point; Develop proof-of-concept, user-friendly interfaces. To do this a group of national and international experts have been assembled to guide the development of these tools explicitly for use in primary, secondary and tertiary care. This needs to be done while ensuring that this novel approach combines data on all genetic, lifestyle/hormonal, clinical and imaging risk factors has utility and accuracy for each level of healthcare for breast, ovarian and prostate cancer.
|Start date:||1st July 2016|
|End date:||30th June 2019|
|Contact person:||Dr Chantal Babb de Villiers|
|Contact Details:||Primary Care Unit
Strangeways Research Laboratory
Dr Fiona Walter, Primary Care Unit, Department of Public Health & Primary Care.
Dr Antonis Antoniou, Centre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care / Department of Oncology.
Dr Marc Tischkowitz, Department of Medical Genetics, Cambridge University Hospitals.
|Funding Organisation:||Cancer Research UK (CRUK) (UK)|
|Further Information, References and Publications|
|See more details on the PCU CANCER GROUP page for CanRisk|